SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Standard BioTools Inc. (Nasdaq – LAB)

BALA CYNWYD – October 4, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Standard BioTools Inc.(“Standard BioTools” or the “Company”) (Nasdaq – LAB) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the merger of the Company with SomaLogic (Nasdaq: SLGC) in an all-stock transaction. Under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon the close of the transaction, Standard BioTools shareholders will own approximately 43% of the combined company, and SomaLogic shareholders will own approximately 57% of the combined company on a fully diluted basis.

The investigation concerns whether the Standard BioTools Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Standard BioTools shareholders in the combined company.

If you own shares of Standard BioTools stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.